The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 May 2026•

1 min read

FDA Approves AbbVie's DECNUPAZ for Rare Blood Cancer Treatment

Key Facts

1The U.S. FDA approved DECNUPAZ (pivekimab sunirine-pvzy) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

2DECNUPAZ marks AbbVie's first antibody-drug conjugate (ADC) approved for blood cancer.

In a move that strengthens the company's position in the specialized pharmaceuticals sector, the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first antibody-drug conjugate (ADC) approved for blood cancer. According to reports, DECNUPAZ can be initiated in an outpatient setting, addressing an ultra-rare and aggressive hematologic malignancy with limited existing options.

This approval comes amid intense competition in the oncology space, where peers like Pfizer have reported robust growth in cancer drug revenues in recent quarters per earnings reports. The ADC technology is a strategic pivot for AbbVie to diversify its portfolio beyond Humira, as it seeks to capture market share from competitors like AstraZeneca, which maintains a strong footprint in targeted therapies per market data.

Shares of ABBV stood at $165.40 (close May 27, 2026) as investors digest the regulatory milestone. Looking ahead, market participants will monitor upcoming U.S. economic catalysts, including Initial Jobless Claims, which may influence broader sector sentiment. Analysts will also be watching for company guidance regarding the commercial launch timeline and pricing strategy for the newly approved therapy.